1.13

0.00% 0.00

Cocrystal Pharma Inc (COCP)

Overview News Price History Financials Discussions Forecast Stock Split

Cocrystal Pharma Inc stock is traded at $1.13, with a volume of 42,917. It is up +0.00% in the last 24 hours and up +15.28% over the past month. Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Previous Close:

$1.13

Open:

$1.12

24h Volume:

42,917

Relative Volume:

0.54

Market Cap:

$21.77M

Revenue:

Net Income/Loss:

$-8.83M

P/E Ratio:

-1.5454

EPS:

-0.7312

Net Cash Flow:

$-8.01M

1W Performance:

+2.73%

1M Performance:

+15.28%

6M Performance:

+9.71%

1Y Performance:

-22.65%

1-Day Range:

$1.10

$1.14

1-Week Range:

$1.10

$1.17

52-Week Range:

$0.76

$2.67

Cocrystal Pharma Inc Stock (COCP) Company Profile

Name

Cocrystal Pharma Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(786) 459-1831

Address

19805 N. CREEK PARKWAY, BOTHELL, WA

Employee

Twitter

@cocrystalpharma

Next Earnings Date

2026-08-13

Latest SEC Filings

COCP's Discussions on Twitter

Compare COCP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COCP Cocrystal Pharma Inc	1.13	22.54M	0	-8.83M	-8.01M	-0.7312
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-08-20	Initiated	H.C. Wainwright	Buy

Cocrystal Pharma Inc Stock (COCP) Latest News

Aug 21, 2026

Cocrystal (COCP) director Brosgart files with zero reported holdings - Stock Titan

Aug 21, 2026

Aug 20, 2026

COCP: 5 Million Private Placement with OPKO Health - Smartkarma

Aug 20, 2026

Cocrystal (COCP) Q1 2026 Results: The EPS Result Is Below Expectation in the Reported Period; After Earnings: The Share Price Adds 0.87%Dividend Increase Stocks - vinanet.vn

Aug 20, 2026

Aug 18, 2026

Cocrystal Pharma appoints Carol L. Brosgart to board of directors By Investing.com - Investing.com South Africa

Aug 18, 2026

Form 8K Cocrystal Pharma Inc For: 18 August By Investing.com - Investing.com Nigeria

Aug 18, 2026

Cocrystal Pharma appoints Carol L. Brosgart to board of directors - Investing.com

Aug 18, 2026

Cocrystal Pharma Adds Veteran Leader to Board of Directors - TipRanks

Aug 18, 2026

Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board - Stock Titan

Aug 18, 2026

Aug 17, 2026

Cocrystal Pharma strengthens board with antiviral expert appointment - TipRanks

Aug 17, 2026

Cocrystal Pharma appoints Carol Brosgart to board to bolster antiviral development - TradingView

Aug 17, 2026

Cocrystal Pharma (COCP) appoints antiviral veteran to board - Stock Titan

Aug 17, 2026

Cocrystal Pharma Appoints Antiviral Drug Expert Carol Brosgart to Board - citybiz

Aug 17, 2026

Cocrystal Pharma appoints Carol Brosgart to board of directors By Investing.com - Investing.com Nigeria

Aug 17, 2026

Cocrystal Pharma appoints Carol Brosgart to board of directors - Investing.com

Aug 17, 2026

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - The Manila Times

Aug 17, 2026

Cocrystal Pharma Appoints Carol Brosgart, M.D. to Board of Directors - Quiver Quantitative

Aug 17, 2026

A Gilead veteran joins Cocrystal’s board to guide antiviral drug development - Stock Titan

Aug 17, 2026

Aug 13, 2026

Cocrystal Pharma Q2 Results: EPS Loss Widens to $(0.23), Misses Estimate - scanx.trade

Aug 13, 2026

Cocrystal Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Cocrystal Pharma (COCP) flags going-concern risk amid Q2 2026 loss and $5M raise - Stock Titan

Aug 13, 2026

Cocrystal Pharma Q2 FY26 net loss widens to $3.16 million; R&D expense climbs to $2.14 million - Bitget

Aug 13, 2026

Aug 10, 2026

Cocrystal Pharma’s single oral drug for multiple viruses - drugdiscoverytrends.com

Aug 10, 2026

Cocrystal Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026